These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 16810714)

  • 1. Impact of modelling intra-subject variability on tests based on non-linear mixed-effects models in cross-over pharmacokinetic trials with application to the interaction of tenofovir on atazanavir in HIV patients.
    Panhard X; Taburet AM; Piketti C; Mentré F
    Stat Med; 2007 Mar; 26(6):1268-84. PubMed ID: 16810714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation by simulation of tests based on non-linear mixed-effects models in pharmacokinetic interaction and bioequivalence cross-over trials.
    Panhard X; Mentré F
    Stat Med; 2005 May; 24(10):1509-24. PubMed ID: 15761916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model-based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm.
    Dubois A; Lavielle M; Gsteiger S; Pigeolet E; Mentré F
    Stat Med; 2011 Sep; 30(21):2582-600. PubMed ID: 21793036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BMS issues PK notice regarding ATV + TDF.
    IAPAC Mon; 2003 Sep; 9(9):203. PubMed ID: 14672069
    [No Abstract]   [Full Text] [Related]  

  • 5. Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir.
    Gérard L; Chazallon C; Taburet AM; Girard PM; Aboulker JP; Piketty C
    Antivir Ther; 2007; 12(1):31-9. PubMed ID: 17503745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.
    Chetchotisakd P
    Expert Rev Anti Infect Ther; 2009 Sep; 7(7):801-5. PubMed ID: 19735222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
    Pellegrin I; Breilh D; Ragnaud JM; Boucher S; Neau D; Fleury H; Schrive MH; Saux MC; Pellegrin JL; Lazaro E; Vray M
    Antivir Ther; 2006; 11(4):421-9. PubMed ID: 16856615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients.
    Solas C; Gagnieu MC; Ravaux I; Drogoul MP; Lafeuillade A; Mokhtari S; Lacarelle B; Simon N
    Ther Drug Monit; 2008 Dec; 30(6):670-3. PubMed ID: 18806695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir.
    Crane HM; Kestenbaum B; Harrington RD; Kitahata MM
    AIDS; 2007 Jul; 21(11):1431-9. PubMed ID: 17589189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of tenofovir in AIDS patients.
    Gagnieu MC; Barkil ME; Livrozet JM; Cotte L; Miailhes P; Boibieux A; Guitton J; Tod M
    J Clin Pharmacol; 2008 Nov; 48(11):1282-8. PubMed ID: 18779377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limited sampling strategies for the estimation of atazanavir daily exposure in HIV-infected patients.
    Cattaneo D; Ripamonti D; Baldelli S; Cozzi V; Fucile S; Clementi E
    Fundam Clin Pharmacol; 2013 Apr; 27(2):216-22. PubMed ID: 22044510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
    Moltó J; Santos JR; Valle M; Miranda C; Miranda J; Blanco A; Negredo E; Clotet B
    Ther Drug Monit; 2007 Oct; 29(5):648-51. PubMed ID: 17898658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives.
    Kearney BP; Mathias A
    Pharmacotherapy; 2009 Aug; 29(8):924-9. PubMed ID: 19637945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosine plus tenofovir containing antiretroviral regimen.
    Lowe SH; van Leeuwen E; Droste JA; van der Veen F; Reiss P; Lange JM; Burger DM; Repping S; Prins JM
    Ther Drug Monit; 2007 Oct; 29(5):566-70. PubMed ID: 17898645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women.
    Dumond JB; Nicol MR; Kendrick RN; Garonzik SM; Patterson KB; Cohen MS; Forrest A; Kashuba AD
    Clin Pharmacokinet; 2012 Dec; 51(12):809-22. PubMed ID: 23044523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study.
    Martin DE; Galbraith H; Schettler J; Ellis C; Doto J
    Clin Ther; 2008 Oct; 30(10):1794-805. PubMed ID: 19014835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
    Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
    J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting.
    Calcagno A; Bonora S; Tettoni MC; D'Avolio A; Perri GD; Lanzafame M; Penco G
    J Acquir Immune Defic Syndr; 2009 Nov; 52(3):431-2. PubMed ID: 19858926
    [No Abstract]   [Full Text] [Related]  

  • 20. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers.
    Luber AD; Brower R; Kim D; Silverman R; Peloquin CA; Frank I
    HIV Med; 2007 Oct; 8(7):457-64. PubMed ID: 17760738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.